Tags : American Society of Hematology (ASH) annual meeting

ViewPoints Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and

Tuba Khan February 10, 2021

In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the […]readmore

Tags : American Society of Hematology (ASH) annual meeting

ViewPoints Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : American Society of Hematology (ASH) annual meeting

ViewPoints Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company